Grapefruit juice ingestion significantly reduces talinolol bioavailability

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 4, 2005, Pages 291-301

  Schwarz, Ute I ^a   Seemann, Diana ^b   Oertel, Reinhard ^b   Miehlke, Stephan ^b   Kuhlisch, Eberhard ^b   Fromm, Martin F ^b   Kim, Richard B ^b   Bailey, David G ^b   Kirch, Wilhelm ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TALINOLOL; WATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; DUODENUM BIOPSY; GENETIC POLYMORPHISM; GENOTYPE; GRAPE JUICE; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; URINARY EXCRETION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; BEVERAGES; BLOTTING, WESTERN; CITRUS PARADISI; DUODENUM; FOOD-DRUG INTERACTIONS; GENES, MDR; HUMANS; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; RNA, MESSENGER;

EID: 16344378672     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.11.111     Document Type: Article

References (52)

1. K.S. Lown, D.G. Bailey, R.J. Fontana, S.K. Janardan, C.H. Adair, L.A. Fortlage Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression [see comments] J Clin Invest 99 1997 2545 2553
2. D.G. Bailey, J. Malcolm, O. Arnold, J.D. Spence Grapefruit juice-drug interactions Br J Clin Pharmacol 46 1998 101 110
3. G.C. Kane, J.J. Lipsky Drug-grapefruit juice interactions Mayo Clin Proc 75 2000 933 942
4. G.K. Dresser, J.D. Spence, D.G. Bailey Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 38 2000 41 57
5. P. Schmiedlin-Ren, D.J. Edwards, M.E. Fitzsimmons, K. He, K.S. Lown, P.M. Woster Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins Drug Metab Dispos 25 1997 1228 1233
6. J. Lundahl, C.G. Regardh, B. Edgar, G. Johnsson Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects Eur J Clin Pharmacol 49 1995 61 67
7. J.U. Lundahl, C.G. Regardh, B. Edgar, G. Johnsson The interaction effect of grapefruit juice is maximal after the first glass Eur J Clin Pharmacol 54 1998 75 81
8. G.K. Dresser, D.G. Bailey The effects of fruit juices on drug disposition a new model for drug interactions Eur J Clin Invest 33 Suppl 2 2003 10 16
9. H.C. Walters, A.L. Craddock, H. Fusegawa, M.C. Willingham, P.A. Dawson Expression, transport properties, and chromosomal location of organic anion transporter subtype 3 Am J Physiol Gastrointest Liver Physiol 279 2000 1188 1200
10. D. Kobayashi, T. Nozawa, K. Imai, J. Nezu, A. Tsuji, I. Tamai Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane J Pharmacol Exp Ther 306 2003 703 708
11. P.B. Watkins The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv Drug Deliv Rev 27 1997 161 170
12. R.B. Kim, M.F. Fromm, C. Wandel, B. Leake, A.J. Wood, D.M. Roden The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors J Clin Invest 101 1998 289 294
13. M. Cvetkovic, B. Leake, M.F. Fromm, G.R. Wilkinson, R.B. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab Dispos 27 1999 866 871
14. R.G. Tirona, R.B. Kim Pharmacogenomics of organic anion-transporting polypeptides (OATP) Adv Drug Deliv Rev 54 2002 1343 1352
15. T. Nozawa, K. Imai, J. Nezu, A. Tsuji, I. Tamai Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human J Pharmacol Exp Ther 308 2004 438 445
16. G.K. Dresser, D.G. Bailey, B.F. Leake, U.I. Schwarz, P.A. Dawson, D.J. Freeman Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine Clin Pharmacol Ther 71 2002 11 20
17. U. Wetterich, H. Spahn-Langguth, E. Mutschler, B. Terhaag, W. Rosch, P. Langguth Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers concentration- and dose-dependent absorption in vitro and in vivo Pharm Res 13 1996 514 522
18. U.I. Schwarz, G.K. Dresser, R. Oertel, R.B. Kim Talinolol-verapamil interaction is not solely due to P-glycoprotein inhibition [abstract] Clin Pharmacol Ther 69 2001 85
19. C. de Mey, V. Schroeter, R. Butzer, P. Jahn, K. Weisser, U. Wetterich Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans J Cardiovasc Pharmacol 26 1995 879 888
20. H. Sourgens, J. Schmidt, H. Derendorf Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study Int J Clin Pharmacol Ther 41 2003 22 29
21. T. Gramatté, R. Oertel, B. Terhaag, W. Kirch Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans Clin Pharmacol Ther 59 1996 541 549
22. R. Oertel, K. Richter, B. Trausch, A. Berndt, T. Gramatté, W. Kirch Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum J Chromatogr B Biomed Appl 660 1994 353 363
23. B. Trausch, R. Oertel, K. Richter, T. Gramatté Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man Biopharm Drug Dispos 16 1995 403 414
24. U.I. Schwarz, T. Gramatte, J. Krappweis, A. Berndt, R. Oertel, O. von Richter Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans Clin Pharmacol Ther 65 1999 283 290
25. M.F. Fromm The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans Adv Drug Deliv Rev 54 2002 1295 1310
26. R.B. Kim, B.F. Leake, E.F. Choo, G.K. Dresser, S.V. Kubba, U.I. Schwarz Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2001 189 199
27. I. Cascorbi, T. Gerloff, A. Johne, C. Meisel, S. Hoffmeyer, M. Schwab Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 2001 169 174
28. D.G. Bailey, G.K. Dresser, J.H. Kreeft, C. Munoz, D.J. Freeman, J.R. Bend Grapefruit-felodipine interaction effect of unprocessed fruit and probable active ingredients Clin Pharmacol Ther 68 2000 468 477
29. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano Measurement of protein using bicinchoninic acid Anal Biochem 150 1985 76 85
30. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
31. R. Wolbold, K. Klein, O. Burk, A.K. Nussler, P. Neuhaus, M. Eichelbaum Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 2003 978 988
32. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmoller, A. Johne Functional polymorphisms of the human multidrug-resistance gene multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 97 2000 3473 3478
33. T. Gramatté, R. Oertel Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil Clin Pharmacol Ther 66 1999 239 245
34. R.B. Kim Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab Rev 34 2002 47 54
35. J. Karlsson, S.M. Kuo, J. Ziemniak, P. Artursson Transport of celiprolol across human intestinal epithelial (Caco-2) cells mediation of secretion by multiple transporters including P-glycoprotein Br J Pharmacol 110 1993 1009 1016
36. J.J. Lilja, J.T. Backman, J. Laitila, H. Luurila, P.J. Neuvonen Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol Clin Pharmacol Ther 73 2003 192 198
37. A.J. Dudley, K. Bleasby, C.D. Brown The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers Br J Pharmacol 131 2000 71 79
38. J.W. Jonker, A.H. Schinkel Pharmacological and physiological functions of the polyspecific organic cation transporters OCT1, 2, and 3 (SLC22A1-3) J Pharmacol Exp Ther 308 2004 2 9
39. J.W. Jonker, E. Wagenaar, C.A. Mol, M. Buitelaar, H. Koepsell, J.W. Smit Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene Mol Cell Biol 21 2001 5471 5477
40. J.W. Jonker, E. Wagenaar, S. Van Eijl, A.H. Schinkel Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations Mol Cell Biol 23 2003 7902 7908
41. Y. Honda, F. Ushigome, N. Koyabu, S. Morimoto, Y. Shoyama, T. Uchiumi Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux Br J Pharmacol 143 2004 856 864
42. M. Kool, M. de Haas, G.L. Scheffer, R.J. Scheper, M.J. van Eijk, J.A. Juijn Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines Cancer Res 57 1997 3537 3547
43. P. Borst, R. Evers, M. Kool, J. Wijnholds A family of drug transporters the multidrug resistance-associated proteins J Natl Cancer Inst 92 2000 1295 1302
44. A. Bernsdorf, K. May, C. Kuhnert-Keil, K.U. Möritz, H.K. Kroemer, W. Siegmund Expression of P-glycoprotein and MRP2-deficient rats (GY/TR-) [abstract] Naunyn Schmiedebergs Arch Pharmacol 367 Suppl 1 2003 R110
45. U.I. Schwarz, T. Gramatte, J. Krappweis, R. Oertel, W. Kirch P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int J Clin Pharmacol Ther 38 2000 161 167
46. H. Spahn-Langguth, P. Langguth Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol Eur J Pharm Sci 12 2001 361 367
47. W. Siegmund, K. Ludwig, T. Giessmann, P. Dazert, E. Schroeder, B. Sperker The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol Clin Pharmacol Ther 72 2002 572 583
48. L. Becquemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon Effect of grapefruit juice on digoxin pharmacokinetics in humans Clin Pharmacol Ther 70 2001 311 316
49. A. Johne, K. Kopke, T. Gerloff, I. Mai, S. Rietbrock, C. Meisel Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 2002 584 594
50. T. Gerloff, M. Schaefer, A. Johne, K. Oselin, C. Meisel, I. Cascorbi MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males Br J Clin Pharmacol 54 2002 610 616
51. S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, U. Brinkmann MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine Br J Clin Pharmacol 53 2002 526 534
52. C. Marzolini, E. Paus, T. Buclin, R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33